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Soluble guanylate cyclase activity was measured in 
normal and psoriatic human epidermis. The specific ac-
tivity of guanylate cyclase was determined to be in-
creased 10-fold and 3-fold in involved and uninvolved 
epidermis of psoriatics, respectively, compared to nor-
mal epidermis. Arachidonic acid (5 to 100 P.M) or 12-
hydroxy-5,8,10,14-eicosatetraenoic acid (HETE) (5 to 50 
P.M) stimulated guanylate cyclase activity from involved 
epidermis 2- to 3-fold and from uninvolved epidermis up 
to 2-fold, but these fatty acids had no effect on the 
activity of this cyclase from normal epidermis. These 
results indicate that there is an increase in the cGMP 
biosynthetic capacity of involved epidermis from pso-
riatics that derives from a markedly increased specific 
activity of guanylate cyclase and an alteration in a prop-
erty of this enzyme activity which renders it responsive 
to fatty acids reported to accumulate in this lesion. These 
observations are consistent with the report that an ele-
vated steady-state level of cGMP is one of the conse-
quences of the strikingly altered metabolism of cGMP in 
p soriatic epidermis. 
Cellular accumulation of cyclic 3',5' guanosine monophos-
phate (cGMP) has been shown to occur in association with the 
action of numerous hormonal agents and a variety of other 
naturally occurring, biologically active substances including 
mitogens [1]. Psoriasis is a nonmalignant proliferative skin 
condition in which cellular cGMP steady-state levels have been 
shown to be increased [2,3]. The biochemical basis for the 
increased levels of cellular cGMP that occur in psoriasis or in 
association with other inducible alterations in cell function has 
not yet been defined. Membrane-active agents which promote 
cellular cGMP accumulation' have not been shown to affect the 
activities of either. guan~late cyclase or of cGMP phosphodies-
terase after cell dlsruptlOn [1]. This has led to the suggestion 
[4] that enzy~es invol.ved in the metabolism of cGMP may be 
regulated mdrrectly WIt? r.espect to these biological signals by 
substances generated withm the cell upon stimulation of mem-
brane receptors. 
Polyunsaturat~d fatty acids were among the frrst defined 
naturally occurrmg substances shown to activate guanylate 
cyclase [5-10]. The soluble form of guanylate cyclase fmm 
human platelets was shown to be stimulated by arachidonic 
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acid and structurally related fatty acids as a result of a non-
cooperative interaction with an enzyme site(s) exhibiting rela-
tively high affinity (Ka = 2.1 /LM) for the lipid component [4]. 
Rammarstrom et al ell] have reported that involved psoriatic 
epidermis has strikingly elevated concentrations of arachidonic 
acid (i.e., 25-fold elevated) and 12-hydroxy-5,8,1O,I4-eicosate-
traenoic acid (RETE) (i.e., 8I-fold elevated). This disclosure 
combined with the discovery that a soluble guanylate cyclase 
from at least one source is stimulable by a specific class of 
polyunsaturated fatty acids raised a question regarding the 
influence that the fatty acids which accumulate in psoriasis 
may have on cGMP metabolism in epidermis affected by this 
disorder. 
In this communication, the activity of guanylate cyclase in 
normal and psoriatic human epidermis has been i'llvestigated, 
as well as the effect of arachidonic acid and RETE on this 
enzyme activity. The results indicate that soluble guanylate 
cyclase activity is markedly increased in lesional epidermis, and 
that the enzyme from this site can be stimulated by micro molar 
concentrations of arachidonic acid and RETE, whereas the 
activity from normal epidermis cannot. 
MATERIALS AND METRODS 
Materials 
GTP, dithiothl"eitol (DTT) , and bovine serum albumin were obtained 
from Sigma. Arachidonic acid was purchased from Nu Chek Prep. All 
other reagents were from commercial som ces and of the highest pW'ity 
available. Antibodies against cGMP were prepared in this laboratory 
from goats. Succinyl-cGMP-tyrosine methyl ester from Sigma was 
iodinated according to the method of Steiner, Parker, and Kipnis [12]. 
HETE was generated from arachidonic acid by incubation with purified 
cow platelet lipoxygenase and pmified as previously described [13]. 
Preparation of Soluble Guanylate Cyclase 
Human skin slices were obtained without anesthesia from 7 normal 
volunteers and 4 untreated psoriatic patients. Informed consent was 
obtained from all subjects. Both uninvolved and involved areas of skin 
were sampled from psoriatic patients; the uninvolved specimen was 
taken from an area of skin at least 5 cm from a well-developed plaque. 
A Castroviejo keratotome set to a t issue depth of 0.1 to 0.2 mm for 
normal and uninvolved epidermis and 0.4 mm for involved epidermis 
produced slices 3 cm wide by 8 cm long, which were immediately frozen 
in liquid nitrogen. Histological examina tion revea1ed that the samples 
were predominantly epidermis with little dermis, but the degree of 
dermal contamination was variable. The frozen samples were pulverized 
by mortar and pestle in liquid nitrogen and homogenized with a 
Brinkman Polytron in 50 mM Tris-HCI, pH 7.5, containing 2 mM DTT. 
The homogenates were centrifuged for 60 min at 105,000 xg to separate 
the soluble and particulate cellular fractions. The soluble fractio n was 
removed and assayed within 30 min. 
Guanylate Cyclase Assay 
Activity of the enzyme was measured by a previously described 
modification [14] of the method of Kimma and Murad [15]. Final 
concentrations of the components in the cyclase assay (80 ILl) were 1 
mM GTP, 3 mM MnCh, 5 mM 3-isobutyl-I-methylxanthine and 2 mM 
DTT in 50 mM Tris-HCI, pH 7.5. Fatty acids tested as possible effectors 
of guanylate cyclase were added prior to addition of the reaction 
mixture and enzyme to reaction tubes as previously described [13]. 
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Solvent, containing the lipid component, was evaporated under vacuum 
(lOs to 20s) before addition of the enzyme extract (40 III containing 0.12 
to 1.0 Ilg of protein) followed by the reaction mixture (40 Ill) 5 sec later. 
Appropriate controls representing solvent alone were included [13). 
The cyclase reaction which was determined to be linear with respect to 
time for at least 30 min was conducted at 37°C for the times designated 
and terminated by the addition of 80 III of 110 mM sodium acetate, pH 
4.0, containing 11 mM EDTA followed by heating at 90°C for 3 min. 
Blank reactions were represented by enzyme extract added to the 
sodium acetate/ EDTA solution heated at 90°C for 3 min followed by 
the addition of the reaction mixture. The cGMP formed was converted 
to the 2' -O-acetyl derivative and assayed by radioimmunoassay as 
previously described [13,14)' The protein concentration of the extract 
was determined by the method of Bradford [16). 
Statistical Analysis 
All determinations were conducted in triplicate. Specific activities 
are expressed as picomoles/min/ mg protein ± standard error of the 
mean. Significance levels were established by a paired, 2-sided Student 
t-test. 
RESULTS 
Guanylate Cyclase Activity 
The study of guanylate cyclase from human epidermis was 
confined to the soluble fraction (105,000 g) of activity obtained 
after disruption of rapidly frozen tissue. Guanylate cyclase 
activity from tissue representing each of the clinical states (i.e., 
normal, uninvolved, and involved) was determined to be linear 
for at least 30 min (Fig 1) . Magnesium (5 mM) was determined 
to support only 10 to 15% and Ca2+ (5 mM) less than 10% of the 
activity obtained with Mn2+ (not shown). It was noted in the 
initial studies, such as the one depicted in Fig 1, that the specific 
activity of the guanylate cyclase from involved epidermis was 
considerably greater than that from normal or uninvolved tissue 
samples; the specific activity of the uninvolved was intermedi-
ate with respect to normal and involved epidermis. 
A more thorough examination of guanylate cyclase activity 
from these 3 different sources showed the specific activity to be 
lO-fold greater in involved compared to normal epidermis 
(Table I). The specific activity of the cyclase from uninvolved 
epidermis was significantly greater (ca. 3-fold) than the activity 
from normal tissue, but only one-third of the activity measur-
able in extracts from involved tissue. 
These marked differences in guanylate cyclase activities from 
the different tissue sources were examined kinetically (Fig 2) 
and found to be due clearly to an increased maximum enzyme 
velocity. The value ofKm for GTP in the presence of saturating 
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FIG 1. Time cow'se of soluble epidermal guanylate cyclase activity. 
Reactions were conducted as described in the Methods section in the 
standard reaction mixtw·e. Enzyme activity was obtained from X, nor-
mal epidermis (N); e, uninvolved (U) ; and A, involved (I) psoriatic 
epidermis. 
GUANYLATE CYCLASE IN PSORIATIC EPIDERMIS 235 
Mean 
±SEM 
TABLE 1. Guanylate cyclase specific activities 


























U/ N 3.26 (p < .05) l / N 10.03 (p < .001) 
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FIG 2. Double reciprocal plot of guanylate cyclase activity from 3 
types of epidermis as a function of GTP concentration. Reactions were 
carried out as described in Methods for 10 min in the presence of a 
constant concentration of Mn2+ (3 mM) and a variable concentration of 
GTP 25 IlM to 1 mM). Velocity- ' represents (pmoles cGMP/ min/ mg 
protein) - ' . Source of enzyme activity: X, normal epidermis (N) ; e, 
uninvolved (U) and A, involved (1) psoriatic epidermis. 
Mn2+ (3 mM) is approximately 100 J.LM for the enzyme activities 
from these 3 different types of epidermis. 
Effect of HETE and Arachidonic Acid on Enzyme Activity 
RETE and arachidonic acid, which have been shown to be 
markedly elevated in psoriatic lesions [11] , have virtually no 
influence, in a concentration range of 5 to 50 or 100 J.LM (i.e., 
arachidonate), on soluble guanylate cyclase from normal human 
epidermis (Table II). A markedly different sensi tivity to these 
fatty acids is exhibited by the cyclase from involved epidermis; 
RETE or arachidonic acid at the lowest concen tration of the 
fatty acid tested (i.e., 5 J.LM) promoted significant activation of 
the already lO-fold enhanced basal cyclase activity from in-
volved epidermis. Maximum activation was about 3-fold with 
50 J.LM RETE or 100 P.M arachidonate. Fig 3 provides a graphic 
representation of the concentration dependence of RETE ac-
tivation. With Mg2+ instead ofMn2+ as the divalent cation used 
to support activity, arachidonic acid (25 P.M) produced an acti-
vation of 4-fold (not shown). A 1.5- to 2-fold activation of th e 
guanylate cyclase from uninvolved epidermis was also observed 
with arachidonic acid or its 12-hydroxy analogue, but the degree 
of variation encountered with the enzyme from this group of 
tissues yielded significant results with only tht! highest or next 
to highest (i.e., RETE) concentration of the lipid components 
tested. It is apparent, however, from these results t hat the 
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TABLE II. Effect of HETE or arachidonic acid on guanylate cyclase activity 
Percent of basal activity from corresponding tissue" 
Origin of enzyme /lM HETE /lM Arachidonate 
activity 
5 25 50 5 25 100 
Normal (N) 103 ± 10 89.7 ± 4.1 107 ± 14 88.5 ± 6.3 106 ± 11 104 ± 14 
Uninvolved (U) 129 ± 12 150 ± 13" 171 ± 26" 190 ± 56 212 ± 66 234 ± 65 
Involved (l) 188 + 38" 236 + 16c 288 ± 30" 208 ± 22" 281 ± 33" 320 ± 39" 
" Basal activities from normal, uninvolved, and involved tissues were 0.34, 1.11, and 3.41 pmoles/min/ mg protein, respectively (see Table 1). 
Activities expressed as mean ± SEM. 
" p < .05. 
c p < .01. 
















FIG 3. Percent basal guanylate cyclase specific activity as a function 
of RETE concentration. Reactions were conducted as described in the 
Methods section in the presence of a variable concentration of RETE. 
Source of enzyme activity: x, normal epidermis (N); e, uninvolved (U), 
and. involved (1) psoriatic epidermis. Points represent means ± SEM. 
enzyme from involved and uninvolved epidermis can be acti-
vated by HETE and arachidonic acid, whereas the cyclase from 
normal epidermis cannot. 
DISCUSSION 
This is the fIrst report of the properties of the enzyme 
catalyzing the biosynthesis of cGMP in human epidermis and 
of the characteristics of the guanylate cyclases in normal and 
psoriatic epidermis that distinguish the activities in these 2 
tissues. 
The soluble guanylate cyclase from normal human epidermis 
exhibits certain characteristics common to the enzyme activity 
from other tissue sources including rat epidermis [17], which 
was also studied for comparison in this investigation. The 
preferred specifIcity for Mn2+ as the divalent metal compared 
to Mg2+ or Ca2+ and the abundance of activity in the soluble 
fraction of disrupted cells are characteristics of human and rat 
epidermal guanylate cyclase ordinarily found with this activity 
from other sources [1,18]. The soluble enzyme from rodent and 
human epidermis (i.e., normal, involved, and uninvolved) is not 
responsive, however, to activation by Triton X-lOO (0.5%) (not 
shown) as are the soluble activities from other sources [1,18], 
with the exception of human platelets [4]. 
One characteristic of the species of soluble guanylate cyclase 
from involved psoriatic epidermis which clearly distinguishes it 
from the enzyme activity in normal human epidermis is a 
sensitivity to stimulation by arachidonic acid and HETE. Fatty 
acids have been shown to stimulate both soluble [4,6,19] and 
particulate forms [8-10] of guanylate cyclase from several 
sources but concentrations of the fatty acids ordinarily reported 
to be effective are 1 to 2 orders of magnitude greater than those 
shown to be stimulatory for the cyclase from human psoriatic 
epidermis. SignifIcant activation by concentrations of fatty 
acids below 10 J.LM has been reported previously only for the 
soluble enzyme from human platelets [4]; the platelet enzyme 
exhibits a Ka value for arachidonic acid of 2 J.LM and an inter-
action of one mole of polyunsaturated fatty acid per catalytic 
site of enzyme. The ineffectiveness of Triton X-lOO and effec-
tiveness of 5 J.LM arachidonic acid or HETE to produce approx-
imately half-maximal activation of the cyclase from human 
psoriatic epidermis suggests that a similar specificity with re-
gard to activation by fatty acids may exist for soluble guanylate 
cyclases from psoriatic epidermis and human platelets. Fatty 
acid specificity was not determined in the present studies, but 
the lipid components tested (i.e., arachidonic acid and HETE) 
could be considered to be of special importance because of theil' 
marked accumulation compared to other fatty acid metabolites 
examined in the psoriatic lesion [11]. 
From the data reported by Hammarstrom et al [11], free 
arachidonic acid and HETE can be calculated to accumulate in 
involved epidermis to levels equivalent to approximately 120 
and 13 f.l.M, respectively. These concentrations are within the 
range in which both fatty acids are effective in activating 
psoriatic epidermal guanylate cyclase. On the other hand, the 
concentration of arachidonate and RETE reported by these 
investigators to be present in uninvolved epidermis would pro-
duce little or no effect. 
To minimize any influence that endogenous fatty acids in the 
tissue samples analyzed (e.g., especially from involved epider-
mis) may have had on the activity of guanylate cyclase 
measured in vitro, tissues were diluted 50- to 100-fold in the 
cyclase reaction. Concentrations of arachidonic acid and HETE 
as great as 2.4 and 0.26 J.LM, respectively, could conceivably have 
been present in reaction mixtures containing extracts from 
psoriatic epidermis. It is possible, therefore, that the markedly 
increased guanylate cyclase activity measured in extracts from 
psoriatic epidermis may be partially attributable to an influence 
of endogenous arachidonic acid. However, the appal"ently 
greater sensitivity to exogenous arachidonic acid of guanylate 
cyclase from involved compared to uninvolved psoriatic epider-
mis and the fact that additional (2- and 3-fold) dilutions of the 
extracts from psoriatic tissue were not found to alter the specific 
activity would argue against this possibility. 
The major problem inherent to studies of biopsied psoriatic 
epidermis is the potential interference deriving from cells other 
than those of epidermal origin. In the case of the changes seen 
in guanylate cyclase activity and the alteration in sensitivity to 
stimulation by arachidonic acid and HETE in involved and 
uninvolved epidermis, the major source of error would be 
expected to derive from contaminating platelets. These blood 
elements exhibit approximately 100 times the soluble guanylate 
cyclase specifIc activity found in normal epidermis and a sen-
April 1980 
sitivity to similar concentrations of arachidonic acid (and 
RETE, unpublished observation), but less than half of the 
responsiveness [4] exhibited by t he cyclase from involved epi-
dermis . It is, h owever, highly unlikely t hat th e 10-fold increase 
in th e specific activity of guanylate cyclase of psoriatic epider-
mis can be accounted for by contaminating platelets. It would 
require a volume of whole blood 25 times greater than th e mass 
of tissue analyzed to account for th e lO-fold increase in gua-
n ylate cyclase activity by contaminating platelets, since they 
represent only 0.4% of the total volume of whole blood. 
In th e present study involved and uninvolved epidermis of 
psoriatic patients was compared with epidermis from unaffected 
volunteers. This comparison revealed that th e uninvolved epi-
dermis exhibits characteristics of guanylate cyclase that are 
qualitatively similar to, but quantitatively of a lesser magnitude 
th an, t h e alterations that characterize t h e cyclase from lesional 
epidermis . This apparently altered state of guanylate cyclase in 
uninvolved epidermis suggests a predisposition for the lesion 
and " pre-Iesional" ch an ges in other componen ts that may un-
derly t h e disease process. The apparently altered sensitivity of 
guanylate cyclase activity from psoriatics to fatty acids suggests 
a genetically-linked alteration in primary enzyme structure, or 
t h e production of a component which r enders this enzyme 
susceptible to fatty acid activation. 
Although existing knowledge is incomplete concerning all of 
th e factors th at contribute to maintaining cellular cGMP con-
centration, the results of the present study indicate that the 
steady-state level of cGMP in psoriatic t issu e sh ould be consid-
erably different from that of normal or uninvolved epidermis. 
The 10-fold greater specific activi ty of guanylate cyclase and 3-
fold stimul a tory effect of the elevated endogenous arachidonic 
acid and/ or HETE in lesional epidermis would provide for a 
30-fold greater catalytic capacity to generate cGMP in th e 
involved tissue. This enhanced biosynth etic capacity could 
provide for an increase in the steady-state level of cGMP which 
has been observed in psoriasis and postulated to be associated 
with enhanced rates of cell proliferation [1,20,21]' 
The importance of th ese findings to t h e pathophysiology of 
psoriasis cannot be defined at present, but the observations 
provide an explanation for the increase in cGMP levels observed 
in involved psoriatic epidermis a nd lend fw-th er support to th e 
concept that specific fatty acids and th eir m etabolites m ay 
represent modulators of cellula r guanylate cyclase activity 
[4,5]. Studies are now in progress examining the role of cyclic 
GMP phosphodiesterase in the altered metabolism of this nu -
cleotide in psoriasis. 
The authors wish to acknowledge the support of Drs. Goltz, Dahl, and 
Buselmeier in referring patients for participation in these studies. 
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